The University of Texas System

Case Western Reserve University

University of Kentucky Research Foundation

University of Iowa Research Foundation

Rodeo Therapeutics Corporation

Joseph Ready

Steven L McKnight

Andrew A Pieper

Jef K De Brabander

Sanford D Markowitz

Amar Desai

Stanton L Gerson

Monika Antczak

Bruce Posner

Yongyou Zhang

James K V Willson

Jeffrey M Zigman

Sung Yeun Yang

KiBeom Bae

Andew A Pieper

Hsin-Hsiung Tai

Doug E Frantz

Jay Schneider

William Greenlee

Jenny Hsieh

Yiyuan Yuan

Bin Hu

Melissa Moss

Gelin Wang

Ting Han

Helen Moinova

Won Jin Ho

Noelle Williams

Mukesh K Jain

Deepak Nijhawan

Pano Theodoropoulos

Youngyou Zhang

Mohamed Sabeh

Stephen L Gwaltney

Stephen S Gonzales

Enrique Fernandez

James Kv Wilson

James KV Willson

Bruce A Posner

Kibeom Bae

The disclosure provides methods for storage solutions for preserving DNA methylation patterns over a period of time. The disclosure also provides for methods of using methylated DNA stored in such storage solutions.

Compositions and methods for preserving DNA methylation

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

Compositions and methods of modulating short-chain dehydrogenase activity

Compositions and methods of modulating short-chain dehydrogenase

A method of treating preventing, minimizing, and/or reversing congestive heart failure, cardiomyopathy, and/or reduction of cardiac ejection fraction in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

Inhibitors of short-chain dehydrogenase activity for treating coronary disorders

A method of modulating hematopoietic stem cells and hematopoiesis includes administering to a subject in need thereof a 15-PGDH inhibitor.

Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.

Compositions and methods of modulating 15-PGDH activity

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

Anti-depression compounds

This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death.

Pro-neurogenic compounds

Provided herein are compositions and methods for reducing one or both of axonal degeneration and neuronal cell death associated with a disease or traumatic brain injury. An aminopropyl carbazole agent with potent neuroprotective properties is described. Specifically, (&#x2212;)-(S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine, is proposed as a new pharmacological agent for protecting patients against axonal degeneration and chronic consequences of TBI.

Neuroprotective compounds and use thereof

Growing community of inventors

Carrollton, TX, United States of America

Joseph Ready